Adrenocorticotropic Hormone Receptor Market
Adrenocorticotropic Hormone Receptor Market Size, Share & Trends Analysis Report By Type (AQB-565, BIM-23B065, and Corticotropin), By Application (Hormonal Disorder, Musculoskeletal Disorder, Crushing Disease, and Acromegaly) Forecast Period, (2026-2035)
Industry Overview
Adrenocorticotropic hormone receptor market was valued at $1,042.0 million in 2025 and is projected to reach $1,738.3 million by 2035, growing at a CAGR of 5.3% during the forecast period (2026-2035). The global adrenocorticotropic hormone receptor market is progressing steadily as demand rises for targeted endocrine therapies and precision-driven approaches to hormonal disorder management. Growth is being supported by expanding clinical focus on adrenal and pituitary-related diseases, alongside increasing research activity aimed at selective receptor modulation. Advances in peptide engineering, receptor agonist development, and improved diagnostic characterization of hormone-related pathways are strengthening therapeutic outcomes. As healthcare systems emphasize mechanism-based treatments with improved safety profiles, ACTH receptor–targeted solutions are gaining importance in both clinical and research setting.
Market Dynamics
Rising Prevalence of Hormonal and Adrenal Disorders
The increasing incidence of conditions such as Cushing’s disease, adrenal insufficiency, and other endocrine imbalances is driving demand for therapies targeting ACTH receptors. Improved awareness and diagnostic capabilities are enabling earlier identification of hormone-related disorders, expanding the addressable patient population. Clinicians are seeking treatments that provide precise control of adrenal hormone regulation while minimizing systemic side effects. This growing clinical need is reinforcing investment in ACTH receptor–focused drug development and supporting sustained market growth.
Advancements in Targeted Endocrine Drug Development
Ongoing progress in receptor biology, peptide formulation, and molecular pharmacology is enabling the development of more selective and effective ACTH receptor agonists and modulators. Pharmaceutical companies are focusing on optimizing receptor specificity, dosing stability, and safety profiles to enhance therapeutic outcomes. Increased collaboration between academic research institutions and industry players is accelerating translational research and pipeline expansion. These advancements are strengthening the overall innovation landscape and contributing to the long-term expansion of the global ACTH receptor market.
Market Segmentation
- Based on the type, the market is segmented into AQB-565, BIM-23B065, and corticotropin.
- Based on the application, the market is segmented into hormonal disorder, musculoskeletal disorder, crushing disease, and acromegaly.
AQB-565 Segment to Lead the Market with the Largest Share
The AQB-565 segment is emerging as the most influential component of the global adrenocorticotropic hormone receptor market, supported by its targeted mechanism of action and growing research interest in receptor-specific endocrine therapies. AQB-565 has gained attention for its potential to deliver more controlled modulation of ACTH receptor activity compared with conventional corticotropin-based treatments. This targeted approach helps improve therapeutic precision while reducing off-target hormonal effects, which is increasingly important in the management of complex adrenal and pituitary disorders. Ongoing advancements in peptide engineering, formulation stability, and receptor selectivity are further strengthening the clinical and commercial attractiveness of AQB-565. As pharmaceutical developers continue to prioritize differentiated, mechanism-driven hormone therapies, the AQB-565 segment is expected to retain a dominant share within the overall market.
Hormonal Disorder: A Key Segment in Market Growth
The hormonal disorder segment represents a key driver of growth in the global ACTH receptor market, underpinned by the rising prevalence of adrenal insufficiency, congenital adrenal hyperplasia, Cushing’s disease, and other endocrine imbalances. Healthcare providers increasingly favor receptor-targeted therapies that enable precise regulation of adrenal hormone production while minimizing systemic complications associated with broader hormonal treatments. Pharmaceutical and biotechnology companies are expanding clinical pipelines to address unmet needs in these disorders, supported by improved diagnostic accuracy and earlier disease detection. As treatment strategies shift toward personalized and pathway-specific interventions, demand for ACTH receptor-based therapies in hormonal disorder applications continues to strengthen, reinforcing this segment’s central role in overall market expansion.
Regional Outlook
The global adrenocorticotropic hormone receptor market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Strengthening Endocrine Research and Therapeutic Development Across Europe
Europe is witnessing steady growth in the global adrenocorticotropic hormone (ACTH) receptor market as pharmaceutical companies, academic research centers, and clinical institutions increase their focus on endocrine and hormonal disorder research. Strong emphasis on translational medicine and rare disease management is supporting the development of receptor-targeted therapies across the region. Ongoing investments in clinical research infrastructure and collaborative cross-border programs are enabling faster progression of ACTH receptor candidates from preclinical studies to clinical evaluation. In parallel, Europe’s stringent regulatory and quality standards are encouraging the adoption of well-characterized, mechanism-based hormone therapies. With rising awareness of adrenal and pituitary disorders, the region continues to strengthen its position as a key hub for ACTH receptor research and therapeutic innovation.
North America Region Dominates the Market with Major Share
North America holds a dominant share in the global ACTH receptor market, driven by the strong presence of biopharmaceutical companies, advanced clinical research capabilities, and high healthcare expenditure. The region benefits from a well-established ecosystem supporting endocrine drug development, including robust funding for rare and chronic hormonal disorder research. Increasing clinical trial activity focused on ACTH receptor agonists and antagonists is accelerating product pipeline advancement. Favorable regulatory pathways for orphan and specialty endocrine therapies further support market growth. Additionally, early adoption of novel hormone-modulating treatments by clinicians continues to reinforce North America’s leadership in the global ACTH receptor market.
Market Players Outlook
The major companies operating in the global adrenocorticotropic hormone receptor market include Ipsen S.A., Mallinckrodt Pharmaceuticals plc, Merck KGaA, Novartis AG, Viatris Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In December 2025, Crinetics Pharmaceuticals, Inc. announced that the first patient has been dosed in the CALM-CAH Phase 3 trial of atumelnant, a novel oral ACTH receptor antagonist designed to treat classic congenital adrenal hyperplasia (CAH). The study follows promising Phase 2 results showing reductions in disease biomarkers and supports the advancement of atumelnant toward pivotal clinical validation.
- In January 2026, Crinetics Pharmaceuticals reported positive topline results from the fourth cohort of its Phase 2 study of atumelnant in CAH, showing substantial reductions in androstenedione levels and meaningful glucocorticoid dose reductions in treated patients, reinforcing the candidate’s clinical promise.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global adrenocorticotropic hormone receptor Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Adrenocorticotropic Hormone Receptor Market Sales Analysis – Type | Application ($ Million)
- Adrenocorticotropic Hormone Receptor Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Adrenocorticotropic Hormone Receptor Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Adrenocorticotropic Hormone Receptor Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Adrenocorticotropic Hormone Receptor Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Adrenocorticotropic Hormone Receptor Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Adrenocorticotropic Hormone Receptor Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Adrenocorticotropic Hormone Receptor Market Revenue and Share by Manufacturers
- Adrenocorticotropic Hormone Receptor Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Ipsen S.A.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Mallinckrodt Pharmaceuticals plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck KGaA
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Viatris Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Ipsen S.A.
- Key Company Analysis
- Global Adrenocorticotropic Hormone Receptor Market Sales Analysis by Type ($ Million)
- AQB-565
- BIM-23B065
- Others
- Global Adrenocorticotropic Hormone Receptor Market Sales Analysis by Application ($ Million)
- Hormonal Disorder
- Musculoskeletal Disorder
- Crushing Disease
- Acromegaly
- Regional Analysis
- North American Adrenocorticotropic Hormone Receptor Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Adrenocorticotropic Hormone Receptor Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Adrenocorticotropic Hormone Receptor Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Adrenocorticotropic Hormone Receptor Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Alder Biopharmaceuticals Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AmbioPharm, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Armor Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Avantor, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BCN Peptides S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BIOVECTRA Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ferring B.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hikma Pharmaceuticals PLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mallinckrodt Pharmaceuticals plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novus Biologicals, LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Piramal Pharma Solutions
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- PolyPeptide Group
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Retrophin, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sichuan Xieli Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Upsher-Smith Laboratories, LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- XOMA Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alder Biopharmaceuticals Inc.
1. Global Adrenocorticotropic Hormone Receptor Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global AQB-565 Adrenocorticotropic Hormone Receptor Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global BIM-23B065 Adrenocorticotropic Hormone Receptor Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Corticotropin Adrenocorticotropic Hormone Receptor Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Adrenocorticotropic Hormone Receptor Market Research and Analysis by Application, 2025–2035 ($ Million)
6. Global Adrenocorticotropic Hormone Receptor Market for Hormonal Disorder Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Adrenocorticotropic Hormone Receptor Market for Musculoskeletal Disorder Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Adrenocorticotropic Hormone Receptor Market for Crushing Disease Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Adrenocorticotropic Hormone Receptor Market for Acromegaly Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Adrenocorticotropic Hormone Receptor Market Research and Analysis by Region, 2025–2035 ($ Million)
11. North American Adrenocorticotropic Hormone Receptor Market Research and Analysis by Country, 2025–2035 ($ Million)
12. North American Adrenocorticotropic Hormone Receptor Market Research and Analysis by Type, 2025–2035 ($ Million)
13. North American Adrenocorticotropic Hormone Receptor Market Research and Analysis by Application, 2025–2035 ($ Million)
14. European Adrenocorticotropic Hormone Receptor Market Research and Analysis by Country, 2025–2035 ($ Million)
15. European Adrenocorticotropic Hormone Receptor Market Research and Analysis by Type, 2025–2035 ($ Million)
16. European Adrenocorticotropic Hormone Receptor Market Research and Analysis by Application, 2025–2035 ($ Million)
17. Asia-Pacific Adrenocorticotropic Hormone Receptor Market Research and Analysis by Country, 2025–2035 ($ Million)
18. Asia-Pacific Adrenocorticotropic Hormone Receptor Market Research and Analysis by Type, 2025–2035 ($ Million)
19. Asia-Pacific Adrenocorticotropic Hormone Receptor Market Research and Analysis by Application, 2025–2035 ($ Million)
20. Rest of the World Adrenocorticotropic Hormone Receptor Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Rest of the World Adrenocorticotropic Hormone Receptor Market Research and Analysis by Type, 2025–2035 ($ Million)
22. Rest of the World Adrenocorticotropic Hormone Receptor Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Adrenocorticotropic Hormone Receptor Market Share by Type, 2025 Vs 2035 (%)
2. Global AQB-565 Adrenocorticotropic Hormone Receptor Market Share by Region, 2025 Vs 2035 (%)
3. Global BIM-23B065 Adrenocorticotropic Hormone Receptor Market Share by Region, 2025 Vs 2035 (%)
4. Global Corticotropin Adrenocorticotropic Hormone Receptor Market Share by Region, 2025 Vs 2035 (%)
5. Global Adrenocorticotropic Hormone Receptor Market Share by Application, 2025 Vs 2035 (%)
6. Global Adrenocorticotropic Hormone Receptor for Hormonal Disorder Market Share by Region, 2025 Vs 2035 (%)
7. Global Adrenocorticotropic Hormone Receptor for Musculoskeletal Disorder Market Share by Region, 2025 Vs 2035 (%)
8. Global Adrenocorticotropic Hormone Receptor for Crushing Disease Market Share by Region, 2025 Vs 2035 (%)
9. Global Adrenocorticotropic Hormone Receptor for Acromegaly Market Share by Region, 2025 Vs 2035 (%)
10. Global Adrenocorticotropic Hormone Receptor Market Research and Analysis by Region, 2025–2035 ($ Million)
11. US Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
12. Canada Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
13. UK Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
14. France Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
15. Germany Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
16. Italy Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
17. Spain Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
18. Russia Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
19. Rest of Europe Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
20. India Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
21. China Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
22. Japan Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
23. South Korea Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
24. Australia and New Zealand Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
25. ASEAN Economies Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
26. Rest of Asia-Pacific Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
27. Latin America Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
28. Middle East and Africa Adrenocorticotropic Hormone Receptor Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Adrenocorticotropic Hormone Receptor Market in 2025 is estimated to be around $1,042.0 million.
North America holds the largest share in the Adrenocorticotropic Hormone Receptor Market.
Leading players in the Adrenocorticotropic Hormone Receptor Market include Ipsen S.A., Mallinckrodt Pharmaceuticals plc, Merck KGaA, Novartis AG, Viatris Inc., among others.
The Adrenocorticotropic Hormone Receptor Market is expected to grow at a CAGR of 5.3% from 2026 to 2035.
The Adrenocorticotropic Hormone Receptor Market growth is driven by increasing research on endocrine disorders and rising development of targeted therapies for adrenal-related diseases.
